At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 978 enrolled
Drug / intervention
LY2189265 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)
In Brief
A Phase 3 clinical trial evaluating LY2189265, Exenatide, and 3 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 978 participants across 89 sites in 4 countries.
Detailed Summary
The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes. The participants must also be taking metformin and pioglitazone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesArgentina, Mexico, Puerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedFeb 2010
Primary CompletionNov 2011
Study CompletionMay 2012
TodayJul 2026
First PostedFeb 8, 2010
Enrollment StartFeb 1, 2010
Primary CompletionNov 1, 2011
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.4 years ago
Interventions
LY2189265drug
Exenatidedrug
Placebodrug
Metformindrug
Pioglitazonedrug